Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 15, 2022

SELL
$42.27 - $57.6 $1.43 Million - $1.95 Million
-33,790 Reduced 52.89%
30,095 $1.28 Million
Q2 2022

Aug 15, 2022

BUY
$52.3 - $71.59 $3.34 Million - $4.57 Million
63,885 New
63,885 $3.57 Million
Q1 2022

May 13, 2022

SELL
$51.32 - $68.5 $1.03 Million - $1.37 Million
-20,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$47.03 - $57.12 $940,600 - $1.14 Million
20,000 New
20,000 $1.1 Million
Q4 2020

Feb 08, 2021

SELL
$96.85 - $148.25 $4.2 Million - $6.43 Million
-43,370 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$122.47 - $213.56 $3.32 Million - $5.8 Million
27,140 Added 167.22%
43,370 $6.16 Million
Q2 2020

Aug 13, 2020

BUY
$185.52 - $231.25 $163,257 - $203,500
880 Added 5.73%
16,230 $3.2 Million
Q1 2020

May 14, 2020

BUY
$143.0 - $274.03 $67,210 - $128,794
470 Added 3.16%
15,350 $3.01 Million
Q4 2019

Feb 18, 2020

SELL
$146.12 - $215.82 $1.92 Million - $2.83 Million
-13,110 Reduced 46.84%
14,880 $3.08 Million
Q3 2019

Nov 14, 2019

BUY
$130.44 - $187.64 $52,176 - $75,056
400 Added 1.45%
27,990 $4.27 Million
Q2 2019

Aug 14, 2019

BUY
$111.45 - $128.93 $151,572 - $175,344
1,360 Added 5.18%
27,590 $3.56 Million
Q1 2019

May 14, 2019

BUY
$89.61 - $117.78 $56,454 - $74,201
630 Added 2.46%
26,230 $3.09 Million
Q4 2018

Feb 13, 2019

SELL
$87.81 - $110.65 $1.76 Million - $2.22 Million
-20,070 Reduced 43.95%
25,600 $2.35 Million
Q3 2018

Nov 08, 2018

BUY
$90.63 - $120.22 $498,465 - $661,210
5,500 Added 13.69%
45,670 $5.14 Million
Q2 2018

Aug 13, 2018

BUY
$88.4 - $105.34 $187,408 - $223,320
2,120 Added 5.57%
40,170 $3.7 Million
Q4 2017

Feb 13, 2018

BUY
$84.48 - $104.02 $1.74 Million - $2.15 Million
20,640 Added 118.55%
38,050 $3.57 Million
Q3 2017

Nov 13, 2017

BUY
$73.17 - $103.47 $1.27 Million - $1.8 Million
17,410
17,410 $1.77 Million

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.9B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.